Munich - Delayed Quote EUR

CEL-SCI Corp (LSRM.MU)

Compare
0.3628
-0.0014
(-0.38%)
At close: January 10 at 8:05:04 AM GMT+1
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for LSRM.MU

Recent News: LSRM.MU

View More
CEL-SCI Announces Closing of $5 Million Offering

CEL-SCI Announces Closing of $5 Million Offering
Business Wire 11 days ago
CEL-SCI Announces Pricing of $5 Million Public Offering

CEL-SCI Announces Pricing of $5 Million Public Offering
Business Wire 13 days ago
CEL-SCI Announces Proposed Public Offering of Common Stock

CEL-SCI Announces Proposed Public Offering of Common Stock
Business Wire 15 days ago
CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study
Business Wire 30 days ago

CVM: CRO Selected for Registrational Trial
Zacks Small Cap Research last month
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
Business Wire 2 months ago
FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
Business Wire 2 months ago
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
Business Wire 3 months ago
CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation
Business Wire 3 months ago
CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress
Business Wire 3 months ago
The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance
Business Wire 4 months ago
View More

Related Tickers

1K0.BE IGM Biosciences Inc. R
6.00
0.00%
 
1K0.F IGM Biosciences, Inc.
1.9000
-68.33%
 
1K0.MU IGM Biosciences Inc
4.8000
-21.31%
 
NFX.L Nuformix plc
0.0600
+26.32%
 
OBD.L Oxford BioDynamics Plc
0.9110
-8.90%
 
ATNFW 180 Life Sciences Corp.
0.0100
-4.76%
 
TCBPW TC Biopharm (Holdings) Plc
0.0150
+19.05%
 
CYCCP Cyclacel Pharmaceuticals, Inc.
7.60
-3.55%
 
SYBX Synlogic, Inc.
1.4701
+2.09%
 
PHGE BiomX Inc.
0.7624
+3.10%